Impact of different model structure and prior distribution in continual reassessment method

DOI10.1080/03610918.2018.1476698OpenAlexW2890200610MaRDI QIDQ5087922

Filiz Karaman, Efehan Ulas, Tuba Koç

Publication date: 4 July 2022

Published in: Communications in Statistics - Simulation and Computation (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1080/03610918.2018.1476698

zbMATH Keywords

clinical trialsmaximum tolerated dosephase Idose-response models

Mathematics Subject Classification ID

Statistics (62-XX)

Uses Software

• bcrm

Cites Work

• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Optimal Bayesian-feasible dose escalation for cancer phase I trials
• Bayesian model averaging: A tutorial. (with comments and a rejoinder).
• A Curve‐Free Method for Phase I Clinical Trials
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
• Group Sequential and Adaptive Designs – A Review of Basic Concepts and Points of Discussion
• Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials